title: Histone deacetylases as targets for treatment of multiple diseases.
abstract: HDACs (histone deacetylases) are a group of enzymes that deacetylate histones as well as non-histone proteins. They are known as modulators of gene transcription and are associated with proliferation and differentiation of a variety of cell types and the pathogenesis of some diseases. Recently, HDACs have come to be considered crucial targets in various diseases, including cancer, interstitial fibrosis, autoimmune and inflammatory diseases, and metabolic disorders. Pharmacological inhibitors of HDACs have been used or tested to treat those diseases. In the present review, we will examine the application of HDAC inhibitors in a variety of diseases with the focus on their effects of anti-cancer, fibrosis, anti-inflammatory, immunomodulatory activity and regulating metabolic disorders.
authors: Department of Nephrology, Tongji University School of Medicine, Shanghai East Hospital, Shanghai, China.
authors: Jinhua
authors: J
authors: Tang
authors: Haidong
authors: H
authors: Yan
authors: Shougang
authors: S
authors: Zhuang
mesh_terms: D000107:Acetylation / Q000187:drug effects; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000235:genetics; D001343:Autophagy / Q000235:genetics; D059447:Cell Cycle Checkpoints / Q000235:genetics; D057890:Epigenomics; D005355:Fibrosis / Q000188:drug therapy*; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use*; D006655:Histone Deacetylases / Q000378:metabolism / Q000502:physiology*; D006657:Histones / Q000378:metabolism; D006801:Humans; D007109:Immunity / Q000235:genetics; D056747:Immunomodulation / Q000187:drug effects*; D008659:Metabolic Diseases / Q000188:drug therapy*; D009369:Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D056572:Histone Deacetylase Inhibitors; D006657:Histones; D006655:Histone Deacetylases